Sign inJoin waitlistJoin the waitlist

VM

Vicky Makker

Director, Hematology-Medical Oncology Fellowship Training Program · MSK

Credentials: · · · ·

History

Hematology-Medical Oncology Fellowship · MSK
Present
Endometrial Cancer Program Section · MSK
Present

Research

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology · 2024 · 935 citations
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
New England Journal of Medicine · 2022 · First of 25 authors · 797 citations
Endometrial cancer
Review · Nature Reviews Disease Primers · 2021 · First of 7 authors · Corresponding · 541 citations

CA
Carol Aghajanian
52 papers
NA
Nadeem Abu-Rustum
44 papers
KA
Kaled Alektiar
28 papers
ML
Mario Leitao
28 papers
JM
Jennifer Mueller
27 papers · 2 as a fellow
RG
Rachel Grisham
21 papers · 1 as a fellow
RO
Roisin O'Cearbhaill
21 papers
LE
Lora Ellenson
18 papers
MR
Maria Rubinstein
18 papers · 8 as a fellow
CF
Claire Friedman
16 papers
KC
Karen Cadoo
15 papers
WT
William Tew
15 papers

Clinical trials

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Principal investigator · Terminated · Phase 1
Faeth Therapeutics
2022–2025
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2026
A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2018–2026
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2022